Abstract
Inflammatory bowel disease (IBD) is a chronic recurrent intestinal disease. The incidence rate of IBD is increasing year by year, which seriously endangers human health worldwide. More and more studies have shown that medicinal plants or their main phytochemicals have great potential in the treatment of intestinal diseases. However, the disadvantages of low oral absorption rate, low biological distribution and low systemic bioavailability limit their clinical application to a certain extent. In recent years, the application of nanotechnology has made it possible to treat IBD. Nanoparticles (NPs) drug delivery system has attracted special attention in the treatment of IBD due to its small size, low immunogenicity, surface modification diversity, targeting and other advantages. Synthetic nanoparticles and extracellular vehicles (EVs) can deliver drug components to colon, and play a role in anti-inflammation, regulation of oxidative stress, improvement of intestinal flora, etc. In addition, some medicinal plants can secrete EVs by themselves, and carry biological molecules with therapeutic effects to act on the intestine. Some clinical trials to evaluate the safety, tolerance, toxicity and effectiveness of EVs-loaded drugs in IBD are also progressing steadily. This review introduces that synthetic nanoparticles and medicinal plants derived EVs can play an important role in the treatment of IBD by carrying the effective active phytochemicals of medicinal plants, and discuss the limitations of current research and future research needs, providing a scientific and reliable basis and perspective for further clinical application and promotion.
Introduction: The Delivery Challenge in IBD
Inflammatory Bowel Disease (IBD), which includes Ulcerative Colitis (UC) and Crohn’s Disease (CD), remains a significant global health burden. While medicinal plants like ginger, turmeric, and green tea contain potent phytochemicals with anti-inflammatory and antioxidant properties, their clinical utility is severely limited by poor bioavailability. When administered orally, these compounds are often unstable in the stomach's acidic environment, poorly soluble, and rapidly metabolized before reaching the inflamed colon.
To overcome these barriers, researchers are turning to nanotechnology. By acting as a "Trojan Horse," nano-delivery systems can protect therapeutic cargo and ensure site-specific release in the lower gastrointestinal tract, enhancing efficacy while minimizing systemic side effects.
Technological Frontiers: Synthetic and Natural Nanocarriers
Recent advancements focus on two primary technological categories for drug delivery:
- Synthetic Nanoparticles (NPs): These include engineered platforms such as polymeric NPs (using materials like PLGA and Chitosan) and stimuli-responsive systems. These "smart" particles are designed to release their cargo only in response to specific triggers at the IBD site, such as high Reactive Oxygen Species (ROS) concentrations or specific pH levels. Surface modifications with ligands like folic acid allow these NPs to target receptors overexpressed on inflamed cells.
- Plant-Derived Extracellular Vesicles (PELNVs): This emerging field utilizes exosome-like nanovesicles naturally secreted by plants. PELNVs are noted for their innate biocompatibility and ability to carry a synergistic mix of natural RNAs, proteins, and lipids alongside exogenous drugs.
Key Insights and Therapeutic Mechanisms
- The PELNV Advantage: Unlike synthetic counterparts, plant-derived vesicles are often more easily absorbed by the gut and can be produced more cost-effectively. They naturally target intestinal stem cells and macrophages to upregulate healing factors like IL-10.
- Microbiome Modulation: Effective delivery systems do more than suppress inflammation; they help "re-wild" the gut. For instance, Ramulus mori polysaccharide NPs have shown the ability to restore healthy flora and increase beneficial short-chain fatty acids (SCFAs).
- Targeting Strategies: While small NPs naturally accumulate in leaky, inflamed tissue (passive targeting), adding ligands like mannose or galactose (active targeting) significantly increases uptake by the macrophages that drive the "cytokine storm."
Evidence of Efficacy
Experimental results across various models demonstrate the power of these delivery systems:
- Curcumin (Cur): Delivery via PLGA or starch-based NPs has shown a 30-fold increase in absorption efficiency, significantly reducing Disease Activity Index (DAI) scores in animal models.
- Ginger-Derived EVs (GELNs): These vesicles have been shown to downregulate pro-inflammatory cytokines like TNF-α and IL-6 while promoting intestinal barrier integrity through E-cadherin upregulation.
- Resveratrol (RES): Encapsulation in chitosan-based microsponges or galactosylated PLGA NPs allows for nearly 99% targeted release in the colon, bypassing the rapid metabolism that typically renders RES ineffective.
Limitations and Future Directions
Despite promising pre-clinical data, several hurdles remain. Standardizing the industrial-scale production of PELNVs is complex, and many synthetic systems still suffer from low drug-loading capacity. Most importantly, there is a critical "clinical gap"; while rodent models show success, more human clinical trials (such as the ongoing NCT04879810 for ginger-derived exosomes) are essential to verify safety, long-term toxicity, and real-world homing efficiency in the human gut.
Summary updated